Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Greenworks
301260
5
Tuoxin Pharmaceutical Group
301089
(Q1)Mar 31, 2025 | (FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | -7.43%329.28M | 2.85%1.36B | -4.39%332.2M | -30.93%265.75M | 23.35%401.98M | 36.84%355.71M | 101.65%1.32B | 95.23%347.44M | 104.40%384.76M | 111.58%325.88M |
Operating revenue | -7.43%329.28M | 2.85%1.36B | -4.39%332.2M | -30.93%265.75M | 23.35%401.98M | 36.84%355.71M | 101.65%1.32B | 95.23%347.44M | 104.40%384.76M | 111.58%325.88M |
Cost of revenue | -9.57%156.9M | -1.38%675.42M | -8.65%165.52M | -24.73%143.52M | 15.57%192.88M | 18.74%173.5M | 78.94%684.88M | 83.10%181.19M | 74.00%190.68M | 76.23%166.89M |
Gross profit | -5.40%172.37M | 7.43%680.21M | 0.26%166.67M | -37.02%122.23M | 31.51%209.1M | 60.09%182.21M | 133.74%633.14M | 110.42%166.25M | 146.77%194.08M | 168.03%158.99M |
Operating expense | 21.54%120.34M | 43.00%524.48M | 72.57%185.17M | 30.15%125.44M | 21.95%114.85M | 43.70%99.02M | -14.44%366.77M | -3.98%107.3M | -57.40%96.39M | 100.86%94.18M |
Selling and administrative expenses | 21.54%120.34M | 43.00%524.48M | 72.57%185.17M | 30.15%125.44M | 21.95%114.85M | 43.70%99.02M | -14.44%366.77M | -3.98%107.3M | -57.40%96.39M | 100.86%94.18M |
Operating profit | -37.46%52.03M | -41.54%155.73M | -131.38%-18.5M | -103.29%-3.21M | 45.42%94.25M | 85.22%83.19M | 268.80%266.37M | 280.00%58.94M | 166.19%97.7M | 421.42%64.81M |
Net non-operating interest income expense | -18.37%7.85M | 47.44%39.26M | -11.26%7.86M | 53.80%11.11M | 91.05%10.65M | 93.44%9.61M | 381.62%26.63M | 124.35%8.86M | 398.62%7.23M | 10,617.31%5.57M |
Non-operating interest income | -18.37%7.85M | 47.44%39.26M | -11.26%7.86M | 53.80%11.11M | 91.05%10.65M | 93.44%9.61M | 381.62%26.63M | 124.35%8.86M | 398.62%7.23M | 10,032.73%5.57M |
Other net income (expense) | 427.27%1.12M | 104.74%59K | 2,175.00%415K | 256.50%277K | 71.64%-264K | -188.98%-341K | -217.86%-1.25M | -103.72%-20K | 30.31%-177K | -81.13%-931K |
Gain on sale of security | ---- | -39.17%-1.73M | -6,790.00%-1.38M | 256.50%277K | 71.64%-264K | -212.71%-369K | -217.86%-1.25M | -103.72%-20K | 30.31%-177K | -81.13%-931K |
Other non- operating income (expenses) | 427.27%1.12M | --1.79M | ---- | ---- | ---- | ---341K | ---- | ---- | ---- | ---- |
Income before tax | -34.03%60.99M | -33.14%195.05M | -115.07%-10.22M | -92.20%8.18M | 50.65%104.63M | 85.80%92.46M | 291.11%291.75M | 339.88%67.79M | 171.55%104.75M | 480.34%69.46M |
Income tax | 13.13%16.57M | -23.05%49.98M | -50.99%8.66M | -91.25%1.82M | 38.46%24.85M | 71.61%14.65M | 87.61%64.95M | 351.16%17.67M | -41.41%20.8M | 538.65%17.95M |
Net income | -42.91%44.42M | -36.03%145.07M | -137.66%-18.88M | -92.43%6.36M | 54.89%79.78M | 88.74%77.81M | 221.10%226.8M | 336.14%50.12M | 146.15%83.95M | 462.45%51.51M |
Net income continuous Operations | -42.91%44.42M | -36.03%145.07M | -137.66%-18.88M | -92.43%6.36M | 54.89%79.78M | 88.74%77.81M | 221.10%226.8M | 336.14%50.12M | 146.15%83.95M | 462.45%51.51M |
Minority interest income | ||||||||||
Net income attributable to the parent company | -42.91%44.42M | -36.03%145.07M | -137.66%-18.88M | -92.43%6.36M | 54.89%79.78M | 88.74%77.81M | 221.10%226.8M | 336.14%50.12M | 146.15%83.95M | 462.45%51.51M |
Preferred stock dividends | -0.82%6.78M | 0.14%27.5M | -0.55%6.91M | 0.55%6.91M | 22.16%13.13M | 0.83%6.84M | 138.26%27.46M | 0.29%6.95M | 49.59%6.88M | 10.75M |
Other preferred stock dividends | -47.47%3.22M | -41.68%10.12M | -159.85%-2.24M | 0 | 108.86%6.13M | 17.35M | 3.74M | 6.7M | ||
Net income attributable to common stockholders | -46.92%34.42M | -40.95%107.46M | -159.73%-23.55M | -100.79%-557K | 63.52%66.66M | 105.78%64.85M | 191.54%181.99M | 240.03%39.42M | 137.73%70.37M | 345.11%40.76M |
Basic earnings per share | -46.43%0.15 | -41.77%0.46 | -158.82%-0.1 | -100.79%-0.0024 | 61.11%0.29 | 100.00%0.28 | 189.77%0.79 | 234.21%0.17 | 136.59%0.3 | 350.00%0.18 |
Diluted earnings per share | -44.44%0.15 | -41.56%0.45 | -164.71%-0.11 | -100.79%-0.0024 | 64.71%0.28 | 107.69%0.27 | 187.50%0.77 | 234.21%0.17 | 136.59%0.3 | 325.00%0.17 |
Dividend per share | ||||||||||
Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
Audit Opinions | -- | Unqualified Opinion | -- | -- | -- | -- | -- | -- | -- | -- |